Acceleron Pharma Inc (NASDAQ:XLRN) – Piper Jaffray Companies issued their Q1 2021 EPS estimates for shares of Acceleron Pharma in a report issued on Wednesday, December 11th, Zacks Investment Research reports. Piper Jaffray Companies analyst D. Brill anticipates that the biopharmaceutical company will post earnings per share of ($0.18) for the quarter. Piper Jaffray Companies currently has a “Buy” rating and a $71.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Acceleron Pharma’s Q2 2021 earnings at $0.17 EPS and Q3 2021 earnings at ($0.04) EPS.
Several other brokerages have also recently commented on XLRN. Leerink Swann dropped coverage on Acceleron Pharma in a research note on Tuesday, September 17th. ValuEngine cut Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Monday, December 16th. Morgan Stanley boosted their price target on Acceleron Pharma from $48.00 to $52.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Citigroup lowered their price target on Acceleron Pharma from $61.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. Finally, Oppenheimer set a $58.00 price target on Acceleron Pharma and gave the company a “buy” rating in a research note on Tuesday, September 17th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $59.58.
Shares of NASDAQ XLRN traded down $1.66 during trading hours on Friday, hitting $50.95. The stock had a trading volume of 261,321 shares, compared to its average volume of 316,818. The firm’s 50-day moving average price is $49.06 and its two-hundred day moving average price is $44.30. Acceleron Pharma has a 52 week low of $37.01 and a 52 week high of $54.00. The company has a current ratio of 14.02, a quick ratio of 14.02 and a debt-to-equity ratio of 0.05.
Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.03). The business had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.44 million. Acceleron Pharma had a negative net margin of 353.57% and a negative return on equity of 30.79%. Acceleron Pharma’s revenue for the quarter was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.63) EPS.
Several institutional investors and hedge funds have recently bought and sold shares of XLRN. Tower Research Capital LLC TRC bought a new stake in shares of Acceleron Pharma in the second quarter valued at approximately $89,000. Convergence Investment Partners LLC bought a new stake in shares of Acceleron Pharma in the third quarter valued at approximately $149,000. Bank of Montreal Can boosted its position in shares of Acceleron Pharma by 4,163.0% in the second quarter. Bank of Montreal Can now owns 3,922 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 3,830 shares during the period. Nisa Investment Advisors LLC boosted its position in shares of Acceleron Pharma by 1,947.6% in the third quarter. Nisa Investment Advisors LLC now owns 4,300 shares of the biopharmaceutical company’s stock valued at $170,000 after acquiring an additional 4,090 shares during the period. Finally, Aperio Group LLC bought a new stake in shares of Acceleron Pharma in the second quarter valued at approximately $190,000. 89.38% of the stock is owned by institutional investors.
In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 11,853 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $50.28, for a total transaction of $595,968.84. Following the completion of the sale, the chief financial officer now owns 10,426 shares of the company’s stock, valued at $524,219.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Habib J. Dable sold 3,732 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $51.24, for a total value of $191,227.68. Following the sale, the chief executive officer now directly owns 70,785 shares of the company’s stock, valued at approximately $3,627,023.40. The disclosure for this sale can be found here. Insiders have sold 27,920 shares of company stock valued at $1,434,502 in the last ninety days. Company insiders own 2.50% of the company’s stock.
About Acceleron Pharma
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
